Acyl-CoA:1,2-diacylglycerol acyltransferase Inhibitors
2 drugsAbout Acyl-CoA:1,2-diacylglycerol acyltransferase
Acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT) catalyzes the final step in triglyceride synthesis, a key process for energy storage and lipid metabolism. By regulating triglyceride production, DGAT plays a crucial role in lipid homeostasis.
DGAT is a relevant target for drug development due to its role in triglyceride production, though there is currently no genetic evidence directly linking it to specific diseases. Inhibiting DGAT can potentially modulate lipid levels, making it of interest for various therapeutic areas.
Two FDA-approved drugs, LOVAZA and OMEGA-3-ACID ETHYL ESTERS, target DGAT as small molecules. These drugs are marketed by Apotex and WAYLIS THERAP for other indications.
Top Acyl-CoA:1,2-diacylglycerol acyltransferase Drugs
Apotex and WAYLIS THERAP are the only two companies with approved drugs targeting DGAT.
Low market concentration suggests an opportunity for new entrants, but also highlights potential challenges in demonstrating clinical efficacy.
Acyl-CoA:1,2-diacylglycerol acyltransferase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Acyl-CoA:1,2-diacylglycerol acyltransferase, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Acyl-CoA:1,2-diacylglycerol acyltransferase Clinical Trials 45 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Acyl-CoA:1,2-diacylglycerol acyltransferase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 4 | 13 | 0 | 24% |
| Phase 2 | 11 | 7 | 2 | 2 | 78% |
| Phase 3 | 8 | 6 | 2 | 0 | 75% |
| Phase 4 | 9 | 7 | 2 | 0 | 78% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Acyl-CoA:1,2-diacylglycerol acyltransferase Drug Approval Timeline (2004 - 2004)
The first DGAT-targeting drug was approved in 2004, and the most recent in 2014, spanning 11 years.
The approval timeline suggests a potentially saturated market, requiring strong differentiation for new drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Acyl-CoA:1,2-diacylglycerol acyltransferase. A trial counts if an approved drug acting on Acyl-CoA:1,2-diacylglycerol acyltransferase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.